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TRANSFUSION COMPLICATIONS

An investigation into the possibility of transmission
of tick-borne pathogens via blood transfusion
P.M. Arguin, J. Singleton, L.D. Rotz, E. Marston, T.A. Treadwell, K. Slater,
M. Chamberland, A. Schwartz, L. Tengelsen, J.G. Olson, J.E. Childs,
and the Transfusion-Associated Tick-Borne Illness Task Force

BACKGROUND: Tick-borne illnesses were diagnosed in
a group of National Guard members, including some
who had donated blood a few days before the onset of
symptoms. A voluntary recall of those blood components
was issued and a multistate investigation was conducted
to determine if transfusion-transmitted illness had occurred.
STUDY DESIGN AND METHODS: Donors and recipients were asked to complete questionnaires regarding
symptoms and risk factors for infection and to provide
blood samples for laboratory analysis.
RESULTS: Among National Guard personnel who donated blood, 12 individuals were found to have a confirmed or probable case of Rocky Mountain spotted fever or ehrlichiosis. A total of 320 units (platelets or
packed red cells) from 377 donors were transfused into
129 recipients. Although 10 recipients received units
from National Guard personnel with confirmed or probable infection, none became ill.
CONCLUSION: Transfusion-transmitted illness did not
occur. Despite the awareness of the risk for tick-borne
diseases and the use of tick-preventive measures, many
National Guard personnel reported exposure to ticks. In
addition to augmenting current tick-preventive measures, scheduling blood drives before rather than after
field exercises could further reduce the potential for
transmission of tick-borne pathogens.
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I

atrogenic transmission of tick-borne pathogens by
blood transfusion has been well documented for Babesia species.1-5 There has been one documented case
of Rickettsia rickettsii, the causative agent of Rocky
Mountain spotted fever (RMSF), being transmitted by blood
transfusion. In that case, the donor developed symptoms 3
days after his donation and subsequently died. After a 6-day
incubation period, the recipient also developed symptoms
of fever and headache, and his illness was confirmed as
RMSF by serologic testing.6 Other tick-borne pathogens, including Borrelia and Ehrlichia species, have the same potential, but transmission by transfusion has not yet been
documented.2,7-10
In the southern United States, the two most serious
human diseases resulting from the bite of an infected tick
are RMSF and ehrlichiosis. RMSF is an acute febrile illness
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characterized by malaise, myalgia, headache, and, in approximately two-thirds of the cases, a petechial rash on the
extremities, including the palms and soles. Untreated, the
illness lasts 2-3 weeks with up to 30 percent case fatalities.11,12 There are two clinically similar yet distinct forms
of human ehrlichiosis: human monocytic ehrlichiosis,
caused by E. chaffeensis, and human granulocytic
ehrlichiosis, caused by a not-yet-named Ehrlichia species
closely related to E. equi and E. phagocytophila. Both agents
cause an illness similar to RMSF, usually without the characteristic rash, and frequently with the additional laboratory findings of leukopenia, thrombocytopenia, and elevated hepatic aminotransferases.13 All three pathogens are
transmitted by bites from infected ticks. The antibiotic
treatment of choice is doxycycline.
In June 1997, the Iowa State Department of Public
Health identified 10 Iowa National Guard members with an
acute illness characterized by fever, headache, malaise, and
myalgia; six of these individuals also reported a rash. Guard
members became ill shortly after returning from their 2week, annual field training exercises at a military base in
Arkansas, during which they experienced extensive tick
exposure. In addition, several of the ill guard members reported that they had donated blood 24 to 72 hours before
the onset of their symptoms. Preliminary testing of their
serum samples by the Centers for Disease Control and Prevention (CDC) and Iowa Department of Public Health laboratories detected antibodies reactive with spotted fever
group (SFG) rickettsia in four of the ill guard members.
In response to these reports, a voluntary recall of blood
components collected at the base during three previous
blood drives between May 17 and June 29 was issued on July
3. The CDC, in collaboration with the National Guard and
state health departments, initiated an investigation to determine the number of blood donors who developed a tickborne illness and ascertain if recipients of transfused blood
components developed a tick-borne illness that could be
linked to an infected donor.

MATERIALS AND METHODS
The blood collection agency records were reviewed to identify donors who had participated in blood drives held at the
military base during May through June, 1997. Additional
donors were identified through the National Guard and
state health departments whose personnel attempted to
contact all guard members who trained at that military base
during the training season. Guard members who participated in the blood drives were asked to complete a selfadministered questionnaire that included information
about their training experience at the base, illness experienced at, or since returning from, the military base, and any
associated medical care, prior medical history of tick-borne
disease, tick exposure, and tick-bite prevention measures.

Once a list of all the donors was obtained, the number
and type of components prepared from each donation,
where the components had been distributed (i.e., consignees), and each component’s disposition (e.g., transfused,
destroyed) were ascertained. On the basis of the results of
the donor’s blood tests, physicians of patients who had received potentially infectious, recalled blood components
were contacted. These physicians were advised of the signs
and symptoms of RMSF and ehrlichiosis and the appropriate treatment if disease were detected in a recipient. If a
tick-borne infection was suspected in the recipient, or if a
recipient had received components from a donor subsequently shown to have had a confirmed or probable tickborne disease (see below), then the attending physician was
requested to submit a serum specimen and complete a
questionnaire detailing the recipient’s medical history, recent tick exposure, and their medical condition since receiving the recalled blood component.
Laboratory testing for antibodies reactive with ticktransmitted pathogens and DNA from tick-transmitted
pathogens was first performed on retention samples available from most (98%) of the donated units of blood. Because
serologic confirmation of a case of tick-borne disease requires paired testing of convalescent- and acute-phase
samples, an effort was made to contact all donors through
their National Guard units at least 6 weeks after the original donation. This effort was coordinated by state health
department and National Guard personnel and relied primarily on collections at regular musters. However, donors
not present were repeatedly requested by phone to provide
blood through a local health clinic.
Sera were tested by immunofluorescent assay (IFA) for
IgG and IgM antibodies reactive with R. rickettsii, E.
chaffeensis, and the human granulocytic ehrlichiosis agent
and by an investigational enzyme immunoassay (EIA) for
IgG and IgM antibody to SFG rickettsiae.14,15 An IFA result
was considered positive at a titer of >64 and an EIA result
at a titer of >100 for these agents. Samples from donors reporting an erythema migrans-like rash were also tested by
EIA and, when required, by Western immunoblot, for antibodies to Borrelia burgdorferi, the agent of Lyme disease.16
Total DNA was extracted from whole blood recovered
from the retention samples. Attempts to amplify specific
DNA of rickettsial origin by polymerase chain reaction used
primers for the citrate synthase gene, RpCS.877p and
RpCS.1258n,17 for the detection of R. rickettsii, and primers HE1 and HE3, targeting the 16S ribosomal RNA gene,18
for E. chaffeensis. The detection sensitivity of the R. rickettsii
assay, as applied to control samples of spiked whole blood,
was between 10 and 100 organisms per 200 µL of blood. The
detection sensitivity of the E. chaffeensis assay, as applied
to control samples of spiked whole blood, was 1000 infected
cells per 1 mL of blood.
Cases of RMSF and ehrlichiosis were classified as confirmed, probable, asymptomatic seroconversion, or past
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infection by using both clinical and laboratory criteria
(Table 1). A clinically compatible illness was defined as fever, or rash plus at least one other symptom (e.g., headache,
arthralgia, or malaise).
Data collected from the questionnaires were analyzed
with the use of statistical software (SPSS for Windows version 7.0).19 Written informed consent from participating
donors and recipients was obtained before collection of
questionnaires and whole blood.

RESULTS
Between May 17 and June 29, 1997, 8984 National Guard
members from 10 states (Arkansas, Georgia, Iowa, Illinois,
Kansas, Missouri, Nebraska, Oklahoma, Tennessee, and
Texas) engaged in annual training exercises at the Arkansas military base. Training exercises typically lasted 2 weeks
and principally were conducted away, from the barracks, in
the field. Three separate blood drives were held at the military base on May 29-30, June 11-12, and June 25-26, coincident with the final days of each training session. Participants of those blood drives included the visiting National
Guard members, as well as a few permanent military and
civilian staff members at the military base.
A total of 377 donors were identified who had donated
blood at one of the scheduled blood drives at the military
base (n = 368), or within 4 weeks after having returned home
(n = 9). Of these donors, 306 (81%) completed a questionnaire. The median age of donors was 30 years (range, 19-59
years). Seventy-six percent were male and 1.9 percent were
civilian staff at the base. Thirty-seven donors reported fever or rash plus at least one other symptom after donating
blood. The convalescent-phase serum samples were collected 2 to 18 weeks (mean, 8 weeks) after the date of blood
donation. Twelve of the 37 ill donors also had serologic evidence of recent exposure to either R. rickettsii or E.
chaffeensis (Table 2) and were designated as confirmed or
probable cases. The average approximate incubation period until the onset of symptoms was 7 days. Five persons
sought medical attention (donors 1, 3, 9, 10, and 11 in Table
2) for their illness and one required hospitalization (donor
10) for 2 days. Sixty (16%) of the 377 donors had evidence

of asymptomatic seroconversion: 54 to R. rickettsii and six
to E. chaffeensis. Overall, 14.3 percent (9 of 63) and 40 percent (4 of 10) of the donors with serologic evidence of recent exposure to R. rickettsii and E. chaffeensis, respectively,
reported having a clinically compatible illness. None of the
10 donors tested were positive for antibodies to B.
burgdorferi. Polymerase chain reaction testing for pathogen
DNA was negative on all blood retention samples from the
confirmed and probable cases.
The blood that was collected from the 377 donors was
separated into 1020 components, including packed red
cells, platelets, and plasma. Of these, 320 units (157 packed
red cells and 163 platelets) were transfused into 129 recipients in nine states (Alabama, Arkansas, Illinois, Iowa, Louisiana, Mississippi, Oklahoma, Texas, and Utah). Physicians
of all recipients were contacted, and none of the 129 recipients had developed symptoms that could be attributable to
a tick-borne illness after receiving one of these blood components. Ten recipients received blood from donors who
were confirmed or probable cases (Fig. 1). Physicians of
these recipients were recontacted and reported that since
receiving their transfusions, none of the 10 recipients developed symptoms consistent with a tick-borne illness.
Serum samples were forwarded from six recipients; four
recipients had either died because of their preexisting
medical conditions or were unwilling to participate. Of the
six recipients tested, three had positive serologic results
with the investigational EIA for IgG to SFG rickettsia. A recipient from Arkansas submitted paired sera that yielded
results consistent with past infection with SFG rickettsia,
and recipients from Texas and Mississippi had single positive samples, drawn a minimum of 4 weeks after transfusion, that were consistent with past infection or asymptomatic seroconversion to SFG rickettsia. Corresponding IgM
tests and all IFA results were uniformly negative on these
three recipients.
Tick exposure and awareness were high among the
donors—85 percent (260 of 306) of the questionnaire respondents reported that they had always or sometimes
employed at least one tick-bite preventive measure, such
as using repellent on their skin or wearing a uniform impregnated with tick repellent. However, 75 percent of the

TABLE 1. Case definitions for RMSF spotted fever and ehrlichiosis
Status

Compatible
illness*

Serology

Confirmed case
Probable case

Yes
Yes

Asymptomatic seroconversion
Past infection
Either asymptomatic seroconversion
or past infection

No
No

>Fourfold increase or decrease in paired serum IgG titers by IFA
>Fourfold increase or decrease in paired serum IgM titers by IFA or EIA or
>Fourfold increase or decrease in paired serum IgG titers by EIA or
Single elevated serum IgG or IgM titer by IFA or EIA
>Fourfold increase or decrease in paired serum IgG or IgM titers by IFA or EIA
<Fourfold increase or decrease in paired serum IgG or IgM titers by IFA or EIA

No

Single elevated serum IgG or IgM titer by IFA or EIA

* Fever, or rash plus at least one other symptom.
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TABLE 2. Results of serologic testing and symptoms for confirmed and probable cases of RMSF and ehrlichiosis
Titers
Saw
Donor Antigen 1st sample2nd sample Fever Rash Headache Myalgia Arthralgia Nausea physician Hospitalized
1
2
3
4
5
6
7
8
9
10
11
12

Ec
Ec
Ec
Ec
Rr
Rr
Rr
Rr
Rr
Rr
Rr
Rr
Rr

<64
<64
<64
<64
99
99
99
99
99
99
99
99
99

1,024
2,048
512
64
12,801
6,400
3,200
800
6,400
1600
12,801
1,600
12,801

+
+
+
–

–
+
+
+

+
+
+
–

+
–
+
+

–
–
–
–

+
–
+
–

Y
N
Y
N

N
N
N
N

+
+
–
–
+
+
+
–

–
–
+
+
+
+
+
+

+
+
+
+
+
+
+
+

+
+
–
+
–
–
+
+

+
+
+
–
–
–
+
+

+
+
–
–
–
+
–
+

N
N
N
N
Y
Y
Y
N

N
N
N
N
N
Y
N
N

Diagnosis
Confirmed ehrlichiosis
Confirmed ehrlichiosis
Confirmed ehrlichiosis
Confirmed ehrlichiosis
and probable RMSF
Probable RMSF
Probable RMSF
Probable RMSF
Probable RMSF
Probable RMSF
Probable RMSF
Probable RMSF
Probable RMSF

* Ec = IgG by IFA against E. chaffeensis antigen; Rr = IgM by EIA against spotted fever group rickettsiae.

Tracking of blood components
recalled
1020
components
▲

▲

377 donors

700
components

transfused
▲
320
components non-case donor
▲

confirmed or
probable donor

▲
10
components

▲

▲

10 recipients

310
components

119 recipients

Fig. 1. Tracking of blood components from 377 donors identified as having been in a tick-infested area within the 4 weeks
preceding donation.

donors reported finding ticks on their body while at the
military base, and 33.5 percent reported more than 10 ticks
on their body during the training period. Only four donors
reported prophylactic use of doxycycline.

DISCUSSION
In the follow-up of the National Guard blood donations,
transfusion-associated illness from a tick-borne pathogen
was not demonstrated, although transfusion-associated
infection could not be ruled out in all cases. One recipient
had static IgG titers against SFG rickettsia that were consistent with past infection (Table 3). In addition, two recipients submitted single serum samples that tested positive
for IgG to SFG rickettsia. From these results, it is impossible
to determine if these findings represented past infection,

asymptomatic seroconversion, or nonspecific reactivity
with the investigational EIA. All of the IFA results were negative, as were IgM assays by EIA. All three individuals were
from states where RMSF is endemic, so previous exposure
is a possibility. Because no recipient reported the onset of
symptoms suggestive of a tick-borne infection after their
transfusion, serum samples were not collected from recipients whose donors were asymptomatic seroconverters or
from the seronegative donors who reported being ill with
symptoms suggestive of infection.
Passive infection with tick-borne pathogens through
blood transfusion has been confirmed for one case of RMSF
and multiple cases of babesiosis.2-6 In these cases, there was
a period when the donor was asymptomatic and therefore
not deferred from donating blood, yet parasitemia was sufficient to result in transfusion-related disease. Other bacteria, such as B. burgdorferi and Orientia tsutsugamushi, the
causative rickettsial agent of scrub typhus, can survive in
stored blood products,7-10,20 but these pathogens have not
been linked to transfusion-related disease. Although the
pathogenesis of the human ehrlichiosis is incompletely
understood, it is likely that an asymptomatic period occurs
in which infected individuals have high enough titers of
ehrlichiae circulating in their blood that it would be potentially infectious if transfused. Therefore, the potential for
transfusion-related disease exists, although the magnitude
of the risk is difficult to assess.
There are data to suggest that military training exercises in some locations within the United States place trainees at exceptionally high risk of exposure to ticks21 and tickborne diseases.22,23 In 1989, an outbreak of tick-borne
disease coupled with asymptomatic infections occurred
among military personnel training at the same base investigated in this report; 38 percent of the training participants
were found to have antibodies (single positive titers) against
SFG rickettsia (n = 14 cases) or ehrlichial antigens (n = 2
cases).24 As in this study, the majority (67%) of those persons were asymptomatic or did not have an illness clinically
compatible with RMSF or ehrlichiosis. In 1990, a follow up,
Volume 39, August 1999 TRANSFUSION 831
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TABLE 3. Characteristics of ill donors and results of serologic testing of recipients’ blood
Donor and status
1. Confirmed ehrlichiosis
3. Confirmed ehrlichiosis
4. Confirmed ehrlichiosis
and probable RMSF
5. Probable RMSF
6. Probable RMSF
9. Probable RMSF
10. Probable RMSF

Recipient

Blood component received

Serology*

A
B
C

Platelets
Platelets
Red cells

Rr 1:800, 1:400
Negative
Unable to test

D
E
F
G
H
I
J

Platelets
Platelets
Red cells
Platelets
Platelets
Platelets
Red cells

Rr 1:400
Unable to test
Unable to test
Negative
Negative
Unable to test
Rr 1:100

Interpretation
Prior RMSF

Prior RMSF or asymptomatic
Seroconversion

Prior RMSF or
asymptomatic seroconversion

* Rr = IgG by EIA against spotted fever group rickettsiae (all other IFAs or EIAs for IgM were negative).

prospective, seroepidemiologic study collecting paired preexposure and postexposure sera from 1194 military trainees was conducted at the same Arkansas base.22 Thirty persons (2.5%) seroconverted to R. rickettssii and 15 (1.3%) to
E. chaffeensis, although once again only about 30 percent
of the persons seroconverting reported symptoms indicating a possible tick-borne disease.
The current investigation also identified a number of
confirmed or probable cases of RMSF and ehrlichiosis
among a larger percentage (59 of 71 or 83%) of persons with
asymptomatic seroconversions or past infections. Between
1981 and 1992, the average annual incidence of reported
cases of RMSF was 0.32 case per 100,000 population in the
United States and 1.1 cases per 100,000 in Arkansas.12 Although not directly comparable, the occurrence of probable
RMSF among donors who participated in this investigation
and who also sought medical attention was 3 of 306, the
equivalent of 980 cases per 100,000 population during a 6week interval. In assessing the magnitude of the overall situation, one should also consider the potential importance
of the large fraction of asymptomatic seroconverting donors. An infection that may be subclinical in a healthy
young adult could result in a completely different disease
course when transmitted to sick or otherwise compromised
transfusion recipients.
Although serum samples were not obtained from all
recipients, no one (including those who received components from asymptomatic seroconverting donors) reported
becoming ill with symptoms consistent with a tick-borne
disease.
At the time of the investigation and the voluntary recall of the blood components, the CDC and the Food and
Drug Administration (FDA) advised all individuals who
participated in training exercises at the military base during April through June not to donate blood within 4 weeks
of their departure. In addition, blood drives there were suspended until September, when the tick season usually is
over. On the basis of discussions among representatives
from the CDC, FDA, and the Department of Defense (DOD),
the FDA has concluded that blood or plasma collection at
832 TRANSFUSION Volume 39, August 1999

this military base during the tick season is safe, provided
that no unit is collected more than 48 hours after the potential donor arrives at the base. In addition, the FDA has
determined that these trainees will again be advised not to
donate blood or plasma for at least 4 weeks after leaving the
base.25 DOD, however, decided not to allow blood collections at this military base in 1998 and 1999.
The potential for transfusion of tick-borne pathogens
remains a concern, both within the military and among civilian blood collection agencies. A workshop to review the
epidemiology and biology of tick-borne agents with the
potential to be transmitted by transfusion was held in Georgia, January 1999, to help agencies responsible for the
safety of blood components obtain the background information on these subjects so that appropriate steps can be
taken to reduce the risk of transfusion-related infection
without mandating unrealistic screening procedures at
collection centers.
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